Back to Trades
Total Value
$NaN
Filing Date
Mar 18, 2026
1 transactions
Trade Summary
On Mar 18, 2026, Xu Zhenyu, Chief Scientific Officer, reported $NaN of SOPHiA GENETICS SA (SOPH) across 1 transactions. The filing covers company securities and reflects balanced net activity of $NaN. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- SOPHiA GENETICS SA
- Ticker Symbol
- SOPH
- CIK
- 0001840706
Insider Information
- Name
- Xu Zhenyu
- Role
- Chief Scientific Officer
Filing Details
- Filing Date
- Mar 18, 2026
- Transaction Date
- Mar 18, 2026
- Accession Number
- 0001840706-26-000047
- Form Type
- 3
Want live alerts when Xu Zhenyu trades again?
Download Insider Trades to track SOPH, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)147,840 ordinary shares have been pledged pursuant to lending arrangements.
- (F2)Includes 115,002 ordinary shares issuable upon settlement of four restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 2,704 ordinary shares from a May 18, 2022 grant vesting in equal monthly installments through May 18, 2026; (ii) 37,833 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 32,027 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (iv) 42,438 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.
- (F3)The share options are fully vested and exercisable.
- (F4)The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.
- (F5)The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.
- (F6)The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.